Last reviewed · How we verify
BIA 6-512
BIA 6-512 is a Small molecule drug developed by Bial - Portela C S.A.. It is currently in Phase 1 development. Also known as: Trans-resveratrol.
At a glance
| Generic name | BIA 6-512 |
|---|---|
| Also known as | Trans-resveratrol |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIA 6-512 CI brief — competitive landscape report
- BIA 6-512 updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI
Frequently asked questions about BIA 6-512
What is BIA 6-512?
BIA 6-512 is a Small molecule drug developed by Bial - Portela C S.A..
Who makes BIA 6-512?
BIA 6-512 is developed by Bial - Portela C S.A. (see full Bial - Portela C S.A. pipeline at /company/bial-portela-c-s-a).
Is BIA 6-512 also known as anything else?
BIA 6-512 is also known as Trans-resveratrol.
What development phase is BIA 6-512 in?
BIA 6-512 is in Phase 1.
Related
- Manufacturer: Bial - Portela C S.A. — full pipeline
- Also known as: Trans-resveratrol
- Compare: BIA 6-512 vs similar drugs
- Pricing: BIA 6-512 cost, discount & access